SAN FRANCISCO, Nov. 5 - Ciphergen Biosystems said today it expanded an agreement with Novartis to conduct compound profiling for the pharmaceutical company.
Ciphergen will use its SELDI ProteinChip systems and Biomarker Discovery Centers to evaluate samples for Novartis, according to the company.
Financial details of the agreement were not disclosed.
Ciphergen said the first project is a study with Novartis' oncology business unit to compare serum samples of responder and nonresponder patients given candidate drug treatment.
Click here for more information.